All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YF017 | Anti-MSLN (CBL-YF01) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF001 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YF018 | Anti-MSLN (CBL-YF01) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF001 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YF056 | Anti-MSLN (CBL-YF013) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF013 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YF057 | Anti-MSLN (CBL-YF013) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF013 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP8482 | A uniCAR [Anti-biotin-dimeric avidin CAR], with a scFv-based CAR Adaptor [Anti-MSLN], a Switchable CAR System | Ovarian cancer | Lentiviral vector | ||||||
CAR-ZP8501 | A uniCAR [Anti-leucine zipper CAR], with a mAb-based CAR Adaptor [Anti-MSLN], a Switchable CAR System | Ovarian cancer | Lentiviral vector | ||||||
CARP-LX-040 | Anti-MSLN h(28ζ) CART, Combined with R59022, a CAR Plus System | Human | CD28-CD3ζ | Lentiviral vector | |||||
CARP-LX-041 | Anti-MSLN h(28ζ) CART, Combined with R59949, a CAR Plus System | Human | CD28-CD3ζ | Lentiviral vector | |||||
CARP-LX-042 | Anti-MSLN h(28ζ) CART, Combined with Sch-58261, a CAR Plus System | Human | P4 | 0 | CD28-CD3ζ | Lentiviral vector | |||
CARP-LX-084 | Anti-MSLN h(BBζ) CART, Combined with R59022, a CAR Plus System | Human | 41BB-CD3ζ | Lentiviral vector | |||||
CARP-LX-085 | Anti-MSLN h(BBζ) CART, Combined with R59949, a CAR Plus System | Human | 41BB-CD3ζ | Lentiviral vector | |||||
CARP-LX-086 | Anti-MSLN h(BBζ) CART, Combined with Sch-58261, a CAR Plus System | Human | P4 | 0 | 41BB-CD3ζ | Lentiviral vector | |||
XS-0722-YF48 | TS-Fluc Anti-Human MSLN scFv (SS1) CD28-CD3ζ CAR, pCDCAR1 | Human | SS1 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF49 | TS-Fluc Anti-Human MSLN scFv (m912) CD28-CD3ζ CAR, pCDCAR1 | Human | m912 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF50 | TS-Fluc Anti-Human MSLN scFv (CBL-YF049) CD28-CD3ζ CAR, pCDCAR1 | Human | CBL-YF049 | Humanized | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF51 | TS-Fluc Anti-Human MSLN scFv (M5) CD28-CD3ζ CAR, pCDCAR1 | Human | M5 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF108 | TS-Fluc Anti-Human MSLN scFv (SS1) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | SS1 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF109 | TS-Fluc Anti-Human MSLN scFv (m912) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | m912 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF110 | TS-Fluc Anti-Human MSLN scFv (CBL-YF049) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | CBL-YF049 | Humanized | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF229 | TS-IL15 SA Anti-Human MSLN scFv (m912) CD28-CD3ζ CAR, pCDCAR1 | Human | m912 | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF230 | TS-IL15 SA Anti-Human MSLN scFv (CBL-YF049) CD28-CD3ζ CAR, pCDCAR1 | Human | CBL-YF049 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-YF231 | TS-IL15 SA Anti-Human MSLN scFv (M5) CD28-CD3ζ CAR, pCDCAR1 | Human | M5 | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION